All In Biotech

NDA 205613 · Salix

Uceris

Budesonide · Rectal · Corticosteroid

Last checked: Nov 20, 2026Latest source record: Apr 9, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Oct 7, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

592

206 Phase 3, 32 recruiting

FAERS reports

42,217

32,256 serious, 3,140 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 1, 2021.

Budesonide rectal foam is indicated for the induction of remission in patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge. Budesonide rectal foam is a glucocorticosteroid indicated for the induction of remission in patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge. ( 1 )

Mechanism: Budesonide has glucocorticosteroid (GCS) activity.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • UCERIS · BUDESONIDE 2MG/ACTUATION · AEROSOL, FOAM, RECTAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Budesonide" as an intervention, any sponsor and status, largest first.

All 592 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective5,106
  • off label use4,635
  • dyspnoea4,608
  • asthma3,635
  • fatigue2,697
  • condition aggravated2,549
  • diarrhoea2,528
  • headache2,513
  • cough2,269
  • pneumonia2,266
  • nausea2,187
  • wheezing2,029

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004138
2005220
2006195
2007197
2008282
2009292
2010320
2011533
2012737
2013796
20141,066
20151,568
20161,791
20172,031
20182,456
20193,073
20203,612
20213,784
20224,065
20234,011
20244,166
20254,033
20262,851

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Uceris* (Budesonide)

2024 spending

$1.0M

Beneficiaries

193

545 claims

Per beneficiary

$5,256

$41.97 per unit

View as table
YearSpending
2020$4,840,451
2021$3,725,120
2022$3,267,277
2023$1,890,841
2024$1,014,315

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,119 on PubMed

Sponsor: Salix

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.